Update from the ongoing phase 1/2 registrational trial of repotrectinib: results in TKI-naïve and TKI-pretreated patients with NTRK fusion-positive advanced solid tumors (TRIDENT-1)

B. Besse; C. Springfeld; C. Baik; A. Hervieu; B. Solomon; V. Moreno; L. Bazhenova; K. Goto; Y. C. Kim; S. Lu; M. Sun; D. Trone; S. Thamake; B. C. Cho; A. de Langen; S. Popat; J. Wolf; D. Moro-Sibilot; J. Fang; A. Drilon

doi:10.1016/S0959-8049(22)01000-0

Update from the ongoing phase 1/2 registrational trial of repotrectinib: results in TKI-naïve and TKI-pretreated patients with NTRK fusion-positive advanced solid tumors (TRIDENT-1)

B. Besse, C. Springfeld, C. Baik, A. Hervieu, B. Solomon, V. Moreno, L. Bazhenova, K. Goto, Y. C. Kim, S. Lu, M. Sun, D. Trone, S. Thamake, B. C. Cho, A. de Langen, S. Popat, J. Wolf, D. Moro-Sibilot, J. Fang, A. Drilon

Department of Internal Medicine

Research output: Contribution to journal › Article › peer-review

Original language	English
Pages (from-to)	S75-S76
Journal	European Journal of Cancer
Volume	174
DOIs	https://doi.org/10.1016/S0959-8049(22)01000-0
Publication status	Published - 2022 Oct

All Science Journal Classification (ASJC) codes

Oncology
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/S0959-8049(22)01000-0

Cite this

Besse, B., Springfeld, C., Baik, C., Hervieu, A., Solomon, B., Moreno, V., Bazhenova, L., Goto, K., Kim, Y. C., Lu, S., Sun, M., Trone, D., Thamake, S., Cho, B. C., de Langen, A., Popat, S., Wolf, J., Moro-Sibilot, D., Fang, J., & Drilon, A. (2022). Update from the ongoing phase 1/2 registrational trial of repotrectinib: results in TKI-naïve and TKI-pretreated patients with NTRK fusion-positive advanced solid tumors (TRIDENT-1). European Journal of Cancer, 174, S75-S76. https://doi.org/10.1016/S0959-8049(22)01000-0

@article{fe5b3de1f5a841068b106e9137c9791f,

title = "Update from the ongoing phase 1/2 registrational trial of repotrectinib: results in TKI-na{\"i}ve and TKI-pretreated patients with NTRK fusion-positive advanced solid tumors (TRIDENT-1)",

author = "B. Besse and C. Springfeld and C. Baik and A. Hervieu and B. Solomon and V. Moreno and L. Bazhenova and K. Goto and Kim, {Y. C.} and S. Lu and M. Sun and D. Trone and S. Thamake and Cho, {B. C.} and {de Langen}, A. and S. Popat and J. Wolf and D. Moro-Sibilot and J. Fang and A. Drilon",

year = "2022",

month = oct,

doi = "10.1016/S0959-8049(22)01000-0",

language = "English",

volume = "174",

pages = "S75--S76",

journal = "European Journal of Cancer",

issn = "0959-8049",

publisher = "Elsevier Limited",

}

Besse, B, Springfeld, C, Baik, C, Hervieu, A, Solomon, B, Moreno, V, Bazhenova, L, Goto, K, Kim, YC, Lu, S, Sun, M, Trone, D, Thamake, S, Cho, BC, de Langen, A, Popat, S, Wolf, J, Moro-Sibilot, D, Fang, J & Drilon, A 2022, 'Update from the ongoing phase 1/2 registrational trial of repotrectinib: results in TKI-naïve and TKI-pretreated patients with NTRK fusion-positive advanced solid tumors (TRIDENT-1)', European Journal of Cancer, vol. 174, pp. S75-S76. https://doi.org/10.1016/S0959-8049(22)01000-0

TY - JOUR

T1 - Update from the ongoing phase 1/2 registrational trial of repotrectinib

T2 - results in TKI-naïve and TKI-pretreated patients with NTRK fusion-positive advanced solid tumors (TRIDENT-1)

AU - Besse, B.

AU - Springfeld, C.

AU - Baik, C.

AU - Hervieu, A.

AU - Solomon, B.

AU - Moreno, V.

AU - Bazhenova, L.

AU - Goto, K.

AU - Kim, Y. C.

AU - Lu, S.

AU - Sun, M.

AU - Trone, D.

AU - Thamake, S.

AU - Cho, B. C.

AU - de Langen, A.

AU - Popat, S.

AU - Wolf, J.

AU - Moro-Sibilot, D.

AU - Fang, J.

AU - Drilon, A.

PY - 2022/10

Y1 - 2022/10

UR - http://www.scopus.com/inward/record.url?scp=85140461432&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85140461432&partnerID=8YFLogxK

U2 - 10.1016/S0959-8049(22)01000-0

DO - 10.1016/S0959-8049(22)01000-0

M3 - Article

AN - SCOPUS:85140461432

SN - 0959-8049

VL - 174

SP - S75-S76

JO - European Journal of Cancer

JF - European Journal of Cancer

ER -

Update from the ongoing phase 1/2 registrational trial of repotrectinib: results in TKI-naïve and TKI-pretreated patients with NTRK fusion-positive advanced solid tumors (TRIDENT-1)

All Science Journal Classification (ASJC) codes

UN SDGs

Access to Document

Other files and links

Cite this